Assessment of Guideline-Nonconcordant Radiotherapy in Medicare Beneficiaries With Metastatic Cancer Near the End of Life, 2015-2017

Patricia Mae G Santos; Noah J Mathis; Kaitlyn Lapen; Stephanie Lobaugh; Divya Yerramilli; Justin E Bekelman; Erin F Gillespie

doi:10.1001/jamahealthforum.2021.4468

Assessment of Guideline-Nonconcordant Radiotherapy in Medicare Beneficiaries With Metastatic Cancer Near the End of Life, 2015-2017

JAMA Health Forum. 2022 Jan 14;3(1):e214468. doi: 10.1001/jamahealthforum.2021.4468. eCollection 2022 Jan.

Authors

Patricia Mae G Santos¹, Noah J Mathis¹, Kaitlyn Lapen¹, Stephanie Lobaugh², Divya Yerramilli¹, Justin E Bekelman³, Erin F Gillespie^{1

4}

Affiliations

¹ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
² Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Department of Radiation Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia.
⁴ Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York.

Abstract

This cross-sectional study uses data from the Centers for Medicare & Medicaid Services to assess the use of professional society guideline-nonconcordant radiotherapy in patients at the end of life.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Cross-Sectional Studies
Death
Humans
Medicare*
Neoplasms*
United States / epidemiology

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States